This article needs to be updated.(May 2018)
Apolipoprotein A-1 Milano (also ETC-216, now MDCO-216) is a naturally occurring mutated variant of the apolipoprotein A1 protein found in human HDL, the lipoprotein particle that carries cholesterol from tissues to the liver and is associated with protection against cardiovascular disease. ApoA1 Milano was first identified by Dr. Cesare Sirtori in Milan, who also demonstrated that its presence significantly reduced cardiovascular disease, even though it caused a reduction in HDL levels and an increase in triglyceride levels.
The ApoA-1 Milano mutation was found by University of Milan researchers after their 1974 investigation of a low HDL / high triglyceride phenotype exhibited by Valerio Dagnoli of Limone sul Garda, a small village in northern Italy.:163 Limone had only 1,000 inhabitants at the time and when blood tests were run on the entire population of the village, the mutation was found to be present in about 3.5% of the local population.:163 The mutation was traced to one man, Giovanni Pomarelli, who lived in the village in the late 18th century and passed it on to his offspring.:163 It is characterised by the replacement of arginine by cysteine at position 173.
Efficacy in Apo A-I/Apo E null mice
Apo A-I Milano has been shown to reduce atherosclerosis in animal models and in a small phase 2 human trial. Recombinant adeno-associated virus 8 (AAV8) mediated Apo A-I Milano gene therapy in combination with low-cholesterol diet induces rapid and significant regression of atherosclerosis in mice.
Efficacy in humans
The first examination of using the mutant ApoA-1 in humans was conducted through a three way collaboration between the University of Milan and the companies Pharmacia and Upjohn in 1996, focusing on treatment of atherosclerosis.:164
The ApoA-1 Milano Trial, published in JAMA in 2003, was the first published placebo controlled, 2 dose level, trial in humans. This was a secondary prevention trial in that those included were individuals who presented to a participating hospital with unstable angina and agreed to consent to a rigorous trial, well beyond usual clinical practice testing and treatment, testing whether this HDL protein variant, which was so effective in animals, would also work in humans. This trial was initiated by Steven Nissen of the Cleveland Clinic after prompting by Roger Newton of Esperion to examine the effects of the mutant protein using intravascular ultrasound imaging.:164 Esperion provided the protein, code named ETC-216, for the duration of the trial.:2293
Use as treatment
Esperion Therapeutics, a high tech venture capital start-up, demonstrated proof of efficacy in both animals and humans, spending many millions of dollars over several years to conduct a single human trial which showed impressive and rapid efficacy by IVUS of coronary arteries. However, over the course of the project they produced only enough ApoA-1 Milano to partially treat thirty out of the forty-five people in the randomized trial, giving them one weekly dose each for five weeks. The results of the trial were published in JAMA (November 5, 2003).
Hoping to develop a more effective treatment than their current product Lipitor, Pfizer purchased and internalized Esperion shortly before JAMA published the results of the Apo A-1 Milano trial.
Currently, no drugs based on ApoA-1 Milano are commercially available. Rights to ApoA-1 Milano were acquired in 2003 by Pfizer. Clinically known as ETC-216, Pfizer did not move trials forward, probably because the complex protein is very expensive to produce and must be administered intravenously, limiting its application compared to oral medications.
Calgary-based SemBioSys Genetics Inc. was a biotechnology company that was using Safflower to develop commercial quantities of ApoA-1 Milano. On October 11, 2011 SemBioSys Genetics signed a multi-product commercialization and platform collaboration agreement with Tasly Pharmaceuticals of Tianjin (China). In May 2012, SemBioSys terminated its operations and announced that Tasly had terminated their agreement.
On the 12th of July 2010 The Medicines Company signed a pharmaceutical development and manufacturing contract with OctoPlus (Netherlands-based drug delivery and drug development company) to perform process development and clinical manufacturing of MDCO-216. After a trial study failed to produce significant enough results compared to other drugs being tested, in 2016 The Medicines Company discontinued development of MDCO-216.
Cardigant Medical is a Los Angeles-based biotech company currently[when?] working to commercialize ApoA-1 Milano to treat various vascular diseases.
- Franceschini G, Sirtori CR, Capurso A, Weisgraber KH, Mahley RW (1980). "A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family" (PDF). J. Clin. Invest. 66 (5): 892–900. doi:10.1172/JCI109956. PMC 371523. PMID 7430351.
- Li, Jie Jack (2009). Triumph of the Heart: The Story of Statins. Oxford University Press. ISBN 9780195323573.
- Maugh II, Thomas H. (November 5, 2003). "Drug for Heart Disease Called Breakthrough". Los Angeles Times.
- Gualandri V, Franceschini G, Sirtori CR, et al. (1985). "AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission". Am. J. Hum. Genet. 37 (6): 1083–97. PMC 1684746. PMID 3936350.
- Weisgraber KH, Rall SC, Bersot TP, Mahley RW, Franceschini G, Sirtori CR (25 February 1983). "Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I" (PDF). J. Biol. Chem. 258 (4): 2508–13. PMID 6401735.
- Wang, L., Tian, F., Arias, A., Yang, M., Sharifi, B. G., & Shah, P. K. (2015). Comparative Effects of Diet-Induced Lipid Lowering Versus Lipid Lowering Along With Apo AI Milano Gene Therapy on Regression of Atherosclerosis. Journal of cardiovascular pharmacology and therapeutics, 21(3), 320-328 doi:10.1177/1074248415610216
- Wang L, Tian F, Arias A, Yang M, Sharifi BG, Shah PK. (2016). Comparative Effects of Diet-Induced Lipid Lowering Versus Lipid Lowering Along With Apo A-I Milano Gene Therapy on Regression of Atherosclerosis. J Cardiovasc Pharmacol Ther. 21(3),320-328. doi:10.1177/1074248415610216 PMID 26499098
- Nissen, Steven E.; Tsunoda, Taro; et al. (November 5, 2003). "Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes". JAMA. 290 (17): 2292–300. doi:10.1001/jama.290.17.2292. PMID 14600188.
- "What's the Deal With the New Plaque Dissolver?".
- ERASE: New HDL Mimetic Shows Promise, S Hughes, 2007, Heartwire
- http://www.drugdevelopment-technology.com/projects/etc/ ETC-216 - Phospholipid Therapy for Coronary Heart Disease (CHD) Patients
- url=http://www.ace-event.org/RNewtonAcePresentation.pdf[permanent dead link]
- "Esperion Product Candidates". Archived from the original on 2009-08-17.
- "TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion". Archived from the original on 2012-02-13.
- "SemBioSys Announces First Quarter Results and Provides Update on Activities". 15 May 2012.
- "Archived copy". Archived from the original on 2010-08-08. Retrieved 2010-08-24.
- "The Medicines Company Acquires ApoA-I Milano From Pfizer". 22 December 2009.[permanent dead link]
- http://www.tradingmarkets.com/news/stock-alert/mdco_the-medicines-company-signs-agreement-with-octoplus-for-mdco-216-1035307.html[permanent dead link]
- "The Medicines Company Discontinues Development of MDCO-216, its Investigational Cholesterol Efflux Promoter | The Medicines Company". www.themedicinescompany.com. Retrieved 2018-06-05.